Windlas Biotech shares have gained nearly 9% in the last three months. SEBI-registered analyst Finkhoz is bullish on the stock, driven by its improving fundamental strength and a bullish chart setup.

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

For many private biotech companies, a successful initial public offering (IPO) remains a major aspiration as it can be a crucial catalyst for growth. It’s a move that can deliver vital funding for ...

Sionna Therapeutics is eyeing a $156 million IPO as the cystic-fibrosis-focused biotech looks to take its lead candidate into phase 2. The Waltham, Massachusetts-based company already unveiled last ...

MapLight Therapeutics Inc. shares jumped as much as 23% after the biotechnology firm raised $258.9 million in an initial ...